These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27766510)

  • 1. Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.
    Godino C; Colombo A; Margonato A
    Clin Drug Investig; 2017 Feb; 37(2):105-120. PubMed ID: 27766510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
    Camici PG; Gloekler S; Levy BI; Skalidis E; Tagliamonte E; Vardas P; Heusch G
    Int J Cardiol; 2016 Jul; 215():1-6. PubMed ID: 27104917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
    Heusch G; Kleinbongard P
    Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure.
    Porres-Aguilar M; Muñoz OC; Abbas A
    Curr Cardiol Rep; 2016 Feb; 18(2):13. PubMed ID: 26768739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivabradine for Treatment of Coronary Artery Disease: From Last Chance Resort to Mainstem of a Reasoned Therapy.
    Lupi A; Rognoni A; Cavallino C; Secco GG; Rosso R; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):4-9. PubMed ID: 25544120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.
    Werdan K; Ebelt H; Nuding S; Höpfner F; Stöckl G; Müller-Werdan U
    Adv Ther; 2015 Feb; 32(2):120-37. PubMed ID: 25687888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A; Tardif JC
    Adv Cardiol; 2006; 43():65-78. PubMed ID: 16936473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
    Borer JS; Deedwania PC; Kim JB; Böhm M
    Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The discovery of the selective If current inhibitor ivabradine (Procoralan): a new therapeutic approach to ischemic heart disease].
    Vilaine JP
    Med Sci (Paris); 2006 Jan; 22(1):87-94. PubMed ID: 16386229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
    Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.
    Deedwania P
    Drugs; 2013 Sep; 73(14):1569-86. PubMed ID: 24065301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate.
    Tagliamonte E; Cirillo T; Rigo F; Astarita C; Coppola A; Romano C; Capuano N
    Adv Ther; 2015 Aug; 32(8):757-67. PubMed ID: 26293212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease.
    Rimoldi SF; Messerli FH; Cerny D; Gloekler S; Traupe T; Laurent S; Seiler C
    Hypertension; 2016 Jun; 67(6):1205-10. PubMed ID: 27091900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
    Filipovský J
    Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.